This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Disis, M. L. Articles by Cheever, M. A. Search for Related Content PubMed PubMed Citation Articles by Disis, M. L. Articles by Cheever, M. A. Social Bookmarking                            What's this?

Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein—Based Vaccine

From the Tumor Vaccine Group, Oncology, University of Washington; Fred Hutchinson Cancer Research Center; and Corixa Corporation, Seattle, WA.

Address reprint requests to Mary L. Disis, MD, Tumor Vaccine Group, Oncology, Box 356527, University of Washington, Seattle, WA 98195-6527; e-mail: ndisis{at}u.washington.edu

PURPOSE: To evaluate the safety of an HER-2/neu intracellular domain (ICD) protein vaccine and to estimate whether vaccine dose impacts immunogenicity.

PATIENTS AND METHODS: Twenty-nine patients with HER-2/neu—overexpressing breast or ovarian cancer and with no evidence of disease after standard therapy received a low- (25 µg), intermediate- (150 µg), or high-dose (900 µg) HER-2/neu ICD protein vaccine. The vaccine was administered intradermally, monthly for 6 months, with granulocyte-macrophage colony-stimulating factor as an adjuvant. Toxicity and both cellular and humoral HER-2/neu—specific immunity was evaluated.

RESULTS: The vaccine was well tolerated. The majority of patients (89%) developed HER-2/neu ICD-specific T-cell immunity. The dose of vaccine did not predict the magnitude of the T-cell response. The majority of patients (82%) also developed HER-2/neu—specific immunoglobulin G antibody immunity. Vaccine dose did not predict magnitude or avidity of the HER-2/neu—specific humoral immune response. Time to development of detectable HER-2/neu—specific immunity, however, was significantly earlier for the high- versus low-dose vaccine group (P = .003). Over half the patients retained HER-2/neu—specific T-cell immunity 9 to 12 months after immunizations had ended.

CONCLUSION: The HER-2/neu ICD protein vaccine was well tolerated and effective in eliciting HER-2/neu—specific T-cell and antibody immunity in the majority of breast and ovarian cancer patients who completed the vaccine regimen. Although the dose of vaccine did not impact the magnitude of T-cell or antibody immunity elicited, patients receiving the highest dose developed HER-2/neu—specific immunity more rapidly than those who received the lowest dose.

Supported by grants from the Cancer Research Treatment Foundation and the National Institutes of Health (NIH), National Cancer Institute grant No. U54-CA090818 (M.L.D), by NIH training grant No. T32 (HL07093; L.G.S.), and by a fellowship from the Department of Defense Breast Cancer Program (DAMD 17-00-1-0492; K.L.K.). Patient care was conducted through the Clinical Research Center Facility at the University of Washington, which is supported through NIH grant No. MO1-RR-00037.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. A. Cheever, J. Schlom, L. M. Weiner, H. K. Lyerly, M. L. Disis, A. Greenwood, O. Grad, W. G. Nelson, and for the Translational Research Working Group Translational Research Working Group Developmental Pathway for Immune Response Modifiers Clin. Cancer Res., September 15, 2008; 14(18): 5692 - 5699. [Abstract] [Full Text] [PDF]

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]

				H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]

				V. Goodell, J. Waisman, L. G. Salazar, C. dela Rosa, J. Link, A. L. Coveler, J. S. Childs, P. A. Fintak, D. M. Higgins, and M. L. Disis Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity Mol. Cancer Ther., March 1, 2008; 7(3): 449 - 454. [Abstract] [Full Text] [PDF]

				D. Atanackovic, N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming PNAS, February 5, 2008; 105(5): 1650 - 1655. [Abstract] [Full Text] [PDF]

				J. W. Park, M. E. Melisko, L. J. Esserman, L. A. Jones, J. B. Wollan, and R. Sims Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2 Overexpressing Breast Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3680 - 3687. [Abstract] [Full Text] [PDF]

				R. Singh and Y. Paterson Immunoediting Sculpts Tumor Epitopes during Immunotherapy Cancer Res., March 1, 2007; 67(5): 1887 - 1892. [Abstract] [Full Text] [PDF]

				S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al. HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405. [Abstract] [Full Text] [PDF]

				G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]

				V. Goodell, L. G. Salazar, N. Urban, C. W. Drescher, H. Gray, R. E. Swensen, M. W. McIntosh, and M. L. Disis Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer J. Clin. Oncol., February 10, 2006; 24(5): 762 - 768. [Abstract] [Full Text] [PDF]

				C. L. Vogel and E. Tan-Chiu Trastuzumab Plus Chemotherapy: Convincing Survival Benefit or Not? J. Clin. Oncol., July 1, 2005; 23(19): 4247 - 4250. [Full Text] [PDF]

				L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]

				R. De Maria, M. Olivero, S. Iussich, M. Nakaichi, T. Murata, B. Biolatti, and M. F. Di Renzo Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer Cancer Res., February 1, 2005; 65(3): 907 - 912. [Abstract] [Full Text] [PDF]

				R. B. Montgomery, E. Makary, K. Schiffman, V. Goodell, and M. L. Disis Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase Cancer Res., January 15, 2005; 65(2): 650 - 656. [Abstract] [Full Text] [PDF]